Lisinopril | Drugs & Aging Skip to main content SpringerLink Account Menu Find a journal
Publish with us Track your research Search Cart 1.Home 2.Drugs & Aging 3.Article Lisinopril A …

Synopsis Lisinopril is an orally active angiotensin-converting enzyme (ACE) inhibitor which
at dosages of 20 to 80mg once daily is effective in lowering blood pressure in all grades of …

The antihypertensive efficacy and safety of lisinopril, a long-acting angiotensin-converting
enzyme inhibitor, were assessed in 40 elderly patients (aged 65 years or over) with mild to …

Lisinopril is a synthetic, nonsulfhydryl, angiotensin‐converting enzyme inhibitor. Its
bioavailability is approximately 25% and is not affected by food. Hepatic metabolism is not …

Angiotensin-converting enzyme inhibitor therapy has been thought to be more effective in
hypertensive patients with normal or elevated levels of renin in the plasma. However …

Lisinopril is a new, nonsulfhydryl angiotensin-converting enzyme inhibitor approved for the
treatment of hypertension. After oral administration, 25–29 percent of the dose is absorbed …

The chemistry, pharmacology, pharmacokinetics, clinical use, adverse effects, and dosage
of lisinopril are reviewed. Lisinopril, a new nonsulfhydryl angiotensin-converting-enzyme …

The safety and tolerability of lisinopril have been assessed in 1,734 hypertensive patients
treated with the agent in a number of clinical trials. Here we compare the clinical and …

The effect of age on the pharmacodynamic responses to converting enzyme inhibitors,
enalapril and enalaprilat was investigated in nine young (22‐30 years) and nine sex …

Summary Lisinopril (MK521), a lysine analogue of enalaprilic acid, the bioactive metabolite
of enalapril, has a longer half-life than enalaprilic acid, and is excreted unchanged in the …